201 related articles for article (PubMed ID: 19073996)
1. Early stopping rules in clinical trials based on sequential monitoring of serious adverse events.
Kramar A; Bascoul-Mollevi C
Med Decis Making; 2009; 29(3):343-50. PubMed ID: 19073996
[TBL] [Abstract][Full Text] [Related]
2. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
Goldman AI; Hannan PJ
Stat Med; 2001 Jun; 20(11):1575-89. PubMed ID: 11391689
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
Sebille V; Bellissant E
Clin Sci (Lond); 2000 May; 98(5):569-78. PubMed ID: 10781388
[TBL] [Abstract][Full Text] [Related]
4. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
5. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
Fay MP; Huang CY; Twum-Danso NA
Clin Trials; 2007; 4(6):598-610. PubMed ID: 18042569
[TBL] [Abstract][Full Text] [Related]
6. Frequentist evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
[TBL] [Abstract][Full Text] [Related]
7. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
8. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
9. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
10. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
12. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
13. On group sequential designs comparing two binomial proportions.
Kepner JL
J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
[TBL] [Abstract][Full Text] [Related]
14. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
15. Sample size reestimation by Bayesian prediction.
Wang MD
Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
[TBL] [Abstract][Full Text] [Related]
16. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
17. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
18. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
20. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
Tan M; Xiong X
Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
